Type 2 diabetes drug improves weight loss, blood sugar in certain Type 1 patients with obesity: Study
A clinical trial led by an Indiana University School of Medicine researcher found that weekly doses of semaglutide - a medication typically prescribed to Type 2 diabetes patients - improved blood sugar levels and weight loss for adult Type 1 diabetes patients who use automated insulin delivery systems and have a body mass index of 30 or higher.
The results, published Monday in NEJM Evidence, represent the first randomized clinical trial exploring semaglutide use in people with Type 1 diabetes, for whom the drug is not currently FDA approved.
"We found that semaglutide was effective in improving time spent in the target blood sugar range and reduction in body weight compared to placebo group," said Viral Shah, MD, lead study author and IU School of Medicine professor of medicine.
Researchers in the 26-week, double-blind study found that 36% of the 36 patients taking semaglutide:
• Achieved target blood glucose levels of over 70% time spent in range of 70 to 180 mg/dl.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.